Wider Access To Naloxone Overdose Medication On Tap In Meeting
This article was originally published in The Tan Sheet
Executive Summary
Behind-the-counter placement of opioid overdose treatment does not resonate with FDA, even as it wants to broaden availability. Naloxone administration has increased among non-medical personnel, which may be a reason FDA wants to discuss broader use of the product.